Evaluation of Role of GnRH Antagonist in Intrauterine Insemination (IUI) Cycles with Mild Ovarian Hyperstimulation (MOH): A Prospective Randomised Study.

Aims and Objective To evaluate the role of GnRH antagonist in prevention of premature LH surge and increasing pregnancy rates in IUI cycle with mild ovarian hyperstimulation (MOH). Study Design Prospective parallel, randomised controlled study.

Couples diagnosed with unexplained, male factor subfertility and with one or both tubes patent were randomised to receive either a GnRH antagonist (study group) or no intervention (control group). All women were treated with clomiphene citrate (D3–D7) followed by HMG. A GnRH antagonist was added when one or more follicles of 16 mm diameter or more were visualised in the study group. When at least one follicle reached a size of ≥18 mm, ovulation was induced by hCG injection. A single IUI was performed 36 h later. The primary outcome was premature LH surge and pregnancy rate. The secondary outcomes were the amount of gonadotropins used, duration of use of GnRH antagonist and incidence and severity of OHSS.

A total of seventy patients attending the infertility clinic in the outpatient department of Obstetrics and Gynecology, of a tertiary care centre, were recruited in the study which was carried out from August 2011 to March 2013. The study group included 34 women and 36 in the control arm. The incidence of premature LH surge was significantly lower in the antagonist group as compared to the control group 2.9 vs. 13.9 %, with a p value of <0.001. The clinical pregnancy rates were similar in both the groups 8.8 vs. 11.1 %, p value being 1.000. The amount of gonadotropins used in GnRH antagonist group was lower than in control group but not statistically significant. Duration of GnRH antagonist was 1.85 ± 0.61 days in the study group.

The delayed administration of GnRH antagonists in MOH with IUI cycles when follicle size is ≥16 mm is beneficial in terms of preventing the occurrence of premature LH surge but with no improvement in pregnancy rates. Similar content being viewed by others

Cantineau AE, Janssen MJ, Cohlen BJ. Synchronised approach for intrauterine insemination in subfertile couples. Cochrane Database Syst Rev. 2010;14(4):006942. doi:10.1002/14651858. Mahani IM, Afnan M. The pregnancy rates with intrauterine insemination (IUI) in superovulated cycles employing different protocols (clomiphen citrate (CC), human menopausal gonadotropin (HMG) and HMG + CC) and in natural ovulatory cycle. J Pak Med Assoc. 2004;54(10):503–5. Cantineau AE, Cohlen BJ, Dutch IUI study group. The prevalence and influence of LH surges in stimulated cycles combined with IUI during a prospective cohort study. Fertil Steril. 2007;88:107–12. doi:10.1016/j.fertnstert.2006.11.136. Bellver J, Labarta E, Bosch E, et al. GnRH agonist administration at the time of implantation does not improve pregnancy outcome in intrauterine insemination cycles: a randomized controlled trial. Fertil Steril. 2010;94(3):1065–71. doi:10.1016/j.fertnstert.2009.04.044. Speroff L, Fritz MA. Clinical gynaecologic endocrinology and infertility. 8th ed. Philadelphia: Lippincott Williams and Wilkins; 2011. p. 1304. Chapter 31, Induction of ovulation. Ragni G, Alagna F, Brigante C, et al. GnRH antagonists and mild ovarian stimulation for intrauterine insemination: a randomized study comparing different gonadotrophin dosages. Hum Reprod. 2004;19(1):54–8. doi:10.1093/humrep/deh023. Al-Inany H, Azab H, El-Khayat W, et al. The effectiveness of clomiphene citrate in LH surge suppression in women undergoing IUI: a randomized controlled trial. Fertil Steril. 2010;94(6):2167–71. doi:10.1016/j.fertnstert.2010.01.069. Lee TH, Lin YH, Seow KM, et al. Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins: randomized trial. Fertil Steril. 2008;90(1):113–20. doi:10.1016/j.fertnstert.2007.06.029. Allegra A, Marino A, Coffaro F, et al. GnRH antagonist induced inhibition of the premature LH surge increases pregnancy rates in IUI-stimulated cycles. A prospective randomized trial. Hum Reprod. 2007;22:101–8. doi:10.1093/humrep/del337. Kamath MS, Ramya R, Bhave P, et al. Effectiveness of GnRH antagonist in intrauterine insemination cycles. Eur J Obstet Gynecol Reprod Biol. 2013;166(2):168–72. doi:10.1016/j.ejogrb.2012.09.023. Bakas P, Konidaris S, Liapis A, et al. Role of gonadotropin-releasing hormone antagonist in the management of subfertile couples with intrauterine insemination and controlled ovarian stimulation. Fertil Steril. 2011;95(6):2024–8. doi:10.1016/j.fertnstert.2011.01.167. Gomez-Palomares JL, Acevedo-Martin B, Chavez M, et al. Multifollicular recruitment in combination with Gonadotropin-releasing hormone antagonist increased pregnancy rates in intrauterine insemination cycles. Fertil Steril. 2008;89(3):620–4. Lambalk CB, Leader A, Olivennes F, et al. Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trial. Hum Reprod. 2006;21(3):632–9. doi:10.1093/humrep/dei386. Steward RG, Gill I, Williams DB, et al. Cetrorelix lowers premature luteinization rate in gonadotropin ovulation induction–intrauterine insemination cycles: a randomized-controlled clinical trial. Fertil Steril. 2011;95(1):434–6. doi:10.1016/j.fertnstert.2010.07.1076. Williams RS, Hillard JB, De Vane G, et al. A randomized, multicenter study comparing the efficacy of recombinant FSH vs recombinant FSH with Ganirelix during superovulation/IUI therapy. Am J Obstet Gynecol. 2004;2:648–51. doi:10.1016/j.ajog.2004.06.072. Graziano A, Caserta D, Piva I, et al. The addition of GnRH antagonists in intrauterine insemination cycles: a pilot study. Eur Rev Med Pharmacol Sci. 2013;17(12):1604–10. Checa MA, Prat M, Robles A, et al. Use of gonadotropin-releasing hormone antagonists to overcome the drawbacks of intrauterine insemination on weekends. Fertil Steril. 2006;3:573–7. doi:10.1016/j.fertnstert.2005.08.040. Kolibianakis E, Bourgain C, Albano C, et al. Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up. Fertil Steril. 2002;78:1025–9. Cantineau AE, Cohlen BJ, Klip H, et al. The addition of GnRH antagonists in intrauterine insemination cycles with mild ovarian hyperstimulation does not increase live birth rates—a randomized, double-blinded, placebo-controlled trial. Hum Reprod. 2011;26(5):110411. doi:10.1093/humrep/der033. Cantineau AE, Cohlen BJ, Heineman MJ. Ovarian stimulation protocols (anti-oestrogens, gonadotropins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with subfertility. Cochrane Database Syst Rev. 2007;2:CD005356. doi:10.1002/14651858.CD005356.pub2. Kosmas IP, Tatsioni A, Kolibianakis EM, et al. Effects and clinical significance of GnRH antagonist administration for IUI timing in FSH superovulated cycles: a metaanalysis. Fertil Steril. 2008;90(2):367–72. doi:10.1016/j.fertnstert.2007.06.064. Luo S, Li S, Jin S, et al. Effectiveness of GnRH antagonist in the management of subfertile couples undergoing controlled ovarian stimulation and intrauterine insemination: a meta-analysis. PLoS One. 2014;9(10):e109133. doi:10.1371/journal.pone.0109133. Author information Authors and Affiliations Corresponding author Ethics declarations Conflict of interest Leena Wadhwa, Rupali Khanna, Taru Gupta, Sangeeta Gupta, Sarika Arora, Sumi Nandwani declare that they have no conflict of interest. Ethical Statement The study was approved by the Institute Ethics committee and is registered with Clinical Trial Registry India CTRI/2012/05/002682. Informed consent Informed consent was obtained from all patients for being included in the study. Additional information Leena Wadhwa, M.D., DNB, is Associate Professor in Department of Obstetrics and Gynecology at ESI-Post Graduate Institute of Medical Science and Research; Rupali Khanna is ex post graduate student and senior resident of Department of Obstetrics and Gynecology at ESI-Post Graduate Institute of Medical Science and Research; Taru Gupta, M.D., is Associate Professor in Department of Obstetrics and Gynecology at ESI-Post Graduate Institute of Medical Science and Research; Sangeeta Gupta, M.D., is Assistant Professor in Department of Obstetrics and Gynecology at ESI-Post Graduate Institute of Medical Science and Research; Sarika Arora, M.D., is Associate Professor in Department of Biochemistry at ESI-Post Graduate Institute of Medical Science and Research; Sumi Nandwani, M.D., is Associate Professor in Department of Microbiology at ESI-Post Graduate Institute of Medical Science and Research. Rights and permissions About this article Cite this article Wadhwa, L., Khanna, R., Gupta, T. et al. Evaluation of Role of GnRH Antagonist in Intrauterine Insemination (IUI) Cycles with Mild Ovarian Hyperstimulation (MOH): A Prospective Randomised Study. J Obstet Gynecol India 66 (Suppl 1), 459–465 (2016). https://doi.org/10.1007/s13224-015-0833-3 Received: Accepted: Published: Issue date: DOI: https://doi.org/10.1007/s13224-015-0833-3